Balloon Dilation for Bladder Neck Contracture
Balloon dilation for bladder neck contracture (BNC) and post-prostatectomy vesicourethral anastomotic stenosis (VUAS) serves two distinct roles: a standalone treatment with modest success (~59% in the Ramchandani 1994 series), and — more commonly today — as the first step before incision or resection, where the combined approach achieves 82–94% patency. Drug-coated balloon (DCB) dilation is an emerging refinement with significantly improved recurrence-free survival vs standard endoscopic treatment in posterior urethral stenosis.[1][2][3]
For the incision counterpart, see Transurethral Incision of BNC (TUIBNC). For the resection counterpart, see Transurethral Bladder Neck Resection (TURBN). For the dedicated DCB / Optilume page (anterior urethra context, with cross-relevant data), see Drug-Coated Balloon. For the broader BNC framework, see Bladder Neck Contracture.
Standalone Balloon Dilation
The Ramchandani 1994 study evaluated fluoroscopically guided transurethral balloon dilation as a standalone treatment for VUAS after radical prostatectomy in 27 patients:[1]
- Success rate: 59% (16/27).
- No de novo urinary incontinence in any patient — a notable advantage over bladder neck incision, where one patient developed de novo incontinence.
- Refractoriness to dilation was attributed to dense scar tissue that could not be adequately disrupted by radial pressure alone.
- Of the 11 patients who failed balloon dilation, 10 underwent subsequent transurethral incision; 70% required repeat attempts or additional dilation.
The lower success of standalone dilation vs incision or resection (59% vs 72–82%) reflects its fundamental limitation: dilation stretches and fractures scar tissue but does not excise or deeply divide it, leaving the fibrotic substrate largely intact.[1][4]
Balloon Dilation as a Preparatory Step
In contemporary practice, balloon dilation is most commonly used as the first step in a combined procedure — dilating the contracture to admit the resectoscope, then performing deep incisions or resection.[2][5]
| Combined approach | Series | Outcome |
|---|---|---|
| 24 Fr balloon → bilateral Collins-knife incisions at 3 & 9 o'clock (Nealon 2022) | n = 123 | 82% single-procedure / 94% two-procedure success[2] |
| Transurethral columnar balloon dilation + holmium laser incision (Sun 2023) — day-surgery model | n = 41 | All completed within 24 h; significant IPSS / Qmax / QoL / PVR improvement at 1 and 6 mo (p < 0.01)[5] |
For the canonical TUIBNC technique (Nealon protocol) including the dilation step, see TUIBNC.
Drug-Coated Balloon (DCB) Dilation
The Berg 2025 real-world comparative study evaluated DCB dilation vs standard endoscopic treatment in 141 patients with posterior urethral stenosis (VUAS and BNC):[3]
| Domain | DCB (n = 65) | Standard (n = 76) | Effect |
|---|---|---|---|
| Recurrence-free survival | Significantly improved | — | p = 0.013 |
| Multivariate predictor of recurrence-free survival | Treatment modality | — | HR 0.40 (95% CI 0.19–0.87, p = 0.021) — 60% reduction |
| Functional outcomes | PVR 55 → 0 mL (p < 0.05); IPSS / Qmax / QoL improved | — | DCB favorable |
An international survey of 102 urologists using DCB found 65% report off-label use for bladder-neck stenoses; higher-volume users (≥ 10 cases / year) were significantly more likely to use DCB for BNC (OR 4.66, 95% CI 1.55–14.03, p = 0.006).[7]
For the device biology, ROBUST trial program, and full DCB evidence base, see Drug-Coated Balloon.
Comparison Across Balloon Approaches
| Approach | Success | Incontinence risk | Key advantage | Key limitation |
|---|---|---|---|---|
| Standalone balloon dilation | 59% | Very low (0% Ramchandani) | Lowest incontinence risk; simple technique | Lowest efficacy; dense scar refractory[1] |
| Balloon dilation + incision / resection | 82–94% (1–2 procedures) | Moderate | Standardized, high patency | Requires resectoscope; sphincter risk[2] |
| Columnar balloon + holmium laser | ~97.6% at 12 mo | 14.6% urge incontinence | Day-surgery feasible | Small series; limited follow-up[5] |
| Drug-coated balloon (Optilume) | 85–90% short-term | Not well characterized | 60% reduction in recurrence (HR 0.40) | Off-label for BNC; limited long-term data[3][7] |
Complications
Balloon dilation carries the lowest complication profile among endoscopic BNC treatments:
| Complication | Rate / note |
|---|---|
| De novo urinary incontinence | 0% with standalone dilation (Ramchandani) — the principal advantage; sphincter mechanism is not deeply disrupted[1] |
| Urge incontinence (combined balloon + holmium laser) | ~14.6%[5] |
| Recurrence | ~41% standalone — usually due to dense scar; primary limitation[1] |
| Bleeding, UTI | Uncommon |
| Perforation / extravasation | Rare; possible with aggressive dilation |
Clinical Positioning
The AUA 2023 guideline notes that all endoscopic techniques have similar success rates (50–80%) for first-time VUAS, and no studies directly compare the different treatment strategies.[8]
In practice:
- Standalone balloon dilation is best suited to mild, early, or first-time BNC without anticipated dense scar — when minimizing incontinence risk is the priority and lower efficacy is acceptable.
- Balloon dilation as a preparatory step before incision / resection is the most widely used combined approach (canonical Nealon protocol).[2]
- Drug-coated balloon dilation is an emerging option with promising early data — 60% reduction in recurrence (Berg 2025) — though it remains off-label for BNC and long-term durability data are needed.[3][7]
Key Principles
- Balloon dilation has two distinct roles: standalone treatment (~59% success) and preparatory step before incision / resection (combined success 82–94%).[1][2]
- Standalone dilation has the lowest incontinence risk of all endoscopic BNC treatments — the principal advantage.[1]
- Standalone is fundamentally limited by dense scar that radial pressure alone cannot disrupt — explains the ~41% recurrence.[1]
- The Nealon 2022 standardized protocol (24 Fr balloon → bilateral 3 & 9 o'clock Collins-knife incisions) is the canonical combined approach with 82% single-procedure and 94% two-procedure success.[2]
- Drug-coated balloon dilation reduces recurrence by ~60% vs standard endoscopic treatment in posterior urethral stenosis (Berg 2025) — promising but off-label for BNC.[3]
- Day-surgery columnar balloon + holmium laser is feasible with high short-term success but limited follow-up.[5]
- DCB use for BNC is concentrated among higher-volume urologists (≥ 10 cases / year, OR 4.66) — suggesting a learning curve and selection effect.[7]
References
1. Ramchandani P, Banner MP, Berlin JW, Dannenbaum MS, Wein AJ. Vesicourethral anastomotic strictures after radical prostatectomy: efficacy of transurethral balloon dilation. Radiology. 1994;193(2):345-9. doi:10.1148/radiology.193.2.7972741.
2. Nealon SW, Bhanvadia RR, Badkhshan S, et al. Transurethral incisions for bladder neck contracture: comparable results without intralesional injections. J Clin Med. 2022;11(15):4355. doi:10.3390/jcm11154355.
3. Berg EK, Mehmedovic S, Askari D, et al. Efficacy of drug-coated balloon dilation vs endoscopic standard treatment in posterior urethral stenosis: a real-world comparative study. Urology. 2025. doi:10.1016/j.urology.2025.07.034.
4. Hudson CN, Damm T, Monn MF. Minimally invasive treatments for posterior urethral stenosis. J Endourol. 2025. doi:10.1177/08927790251371037.
5. Sun J, Xia SQ, Tong Z, Xiao DD, Chen B. Transurethral columnar balloon dilation of the prostate combined with holmium laser incision for bladder neck contracture in day-surgery mode. Lasers Med Sci. 2023;38(1):279. doi:10.1007/s10103-023-03942-8.
6. Kapriniotis K, Loufopoulos I, Apostolopoulou A, Anderson PCB, Papaefstathiou E. Drug-coated balloon treatment for urethral strictures: is this the future? A review of the current literature. J Clin Med. 2025;14(8):2854. doi:10.3390/jcm14082854.
7. Sugrue DD, O'Connor J, Białek Ł, et al. Practices in urethral stricture management with drug-coated balloon dilatation: an international survey. World J Urol. 2026;44(1):285. doi:10.1007/s00345-026-06343-y.
8. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482.